In haplo-identical SCT (haploSCT), the risk of GVHD is virtually nil because of the necessity of T-cell depletion. 1 In HLA-identical SCT human herpes virus type 6 (HHV6) reactivation is correlated with the occurrence of GVHD, but time-correlations between HHV6 and GVHD lack and reports are contradictory. [2] [3] [4] In this report we describe a striking temporal relationship between HHV6 reactivation and GVHD in a patient after extensive T-cell depletion haploSCT.
A 22-year-old, previously healthy male was diagnosed with AML without cytogenetic or molecular abnormalities (World Health Organization classification AML, not otherwise specified). Treatment was started containing cytarabine 200 mg/m 2 (7 days) and idarubicin 12 mg/m 2 (3 days). The patient had a refractory clone. Reinduction with cytarabine 2000 mg/m 2 (6 days) and amsacrine 120 mg/m 2 (3 days) resulted in CR. Because of the high risk of early relapse, absence of an HLA-identical sibling and susceptibility to NK allo-reactivity (donor but not patient HLA-C2 positive and KIR2DL1 present in the donors genome), it was decided to perform a haploSCT. The conditioning regimen was similar to the Perugia protocol and consisted of TBI 8 Gy (day À9), thiotepa 5 mg/kg (days À8 and À7), fludarabine 40 mg/m 2 (days À7 till À3) and anti-thymocyte globulin rabbit 5 mg/kg (days À6 till À2).
1 At the time of transplant the donor was negative for HHV6 immunoglobulin M and positive for immunoglobulin G. The allograft was T-cell depletion (CD34 positive selection, CliniMACS Miltenyi, Bergisch Gladbach, Germany) containing 14.8 Â 10 6 CD34 þ cells/kg and only 0.3 Â 10 4 CD3 þ cells/kg. No post-SCT immune suppression or donor lymphocyte infusions were administered. Engraftment was complete from day þ 26 and persisted. Although not formally tested, the rapid recovery after myeloablative conditioning pointed to full donor chimerism.
At day þ 111 the patient was admitted to the hospital because of extensive skin rash without other symptoms. Because there was no sign of T-cell reconstitution (on day þ 110, 13.9 Â 10 6 /L CD19 þ B-cells were present) at this time (see Figure 1a) , opportunistic infection was thought to be the most likely cause. PCR in plasma was positive (27.668 copies/mL) for HHV6 and negative for the other herpes viruses (Epstein Barr virus, CMV, Herpes Simplex virus and Varicella Zoster virus; both donor and patient were seronegative for CMV at the time of transplant).
Foscarnet treatment was started. In retrospect, HHV6 could be demonstrated in blood from day þ 89 (see Figure 1b ). Skin biopsy, taken on day þ 111, was consistent with GVHD, Glucksberg criteria stage 3, grade II. HHV6 PCR on the sample was positive (C t ¼ 37). Topical steroids were added. The skin rash disappeared and HHV6 viral load decreased to 216 copies/mL. After 10 days foscarnet was discontinued. Because of recurrence of the rash within 1 week a second skin biopsy was performed, confirming the diagnosis of GVHD. The HHV6 viral load had significantly increased to 338.439 copies/mL. Subsequently, severe diarrhoea developed and a biopsy of the terminal ileum was compatible with GVHD; stage 2-3 grade III. HHV6 PCR in plasma had further increased to 26 000 000 copies/mL at that time. Foscarnet was restarted in addition to systemic GVHD treatment (corticosteroids and CYA). Initially, there was a good clinical response but after 2 weeks diarrhoea worsened. Colonic biopsy showed persisting GVHD. Plasma HHV6 PCR was 6168 copies/mL. Corticosteroids were doubled and patient received MSCs Unfortunately, symptoms compatible with thrombotic thrombocytopenic purpura developed and pulmonary haemorrhage occurred, followed by a systemic inflammatory response syndrome (no positive bacterial cultures). He died a few days later (day þ 176).
Autopsy findings were consistent with the described clinical course. Evidence of GVHD of skin and bowel was microscopically found. HHV6 was detected in lungs (C t ¼ 22-24), heart (C t ¼ 34), spleen (C t ¼ 24), ascites (C t ¼ 31) and pleural fluid (C t ¼ 32).
GVHD in this case occurred about 30 days after HHV6 reactivation (that is, the moment HHV6 PCR became detectable in serum; determined retrospectively). During this time patient was severely immune compromised because of the transplant procedure. GVHD worsened (the development of GVHD of the bowel) at the same time as HHV6 PCR increased more than 10 000 fold. Figure 1b shows the enormous rise in immune cells in this period. This is markedly different from usual immune reconstitution after haplo-SCT 5 and could very well represent HHV6-driven (possibly GVHD-inducing) clones. 2 Thus, progressive viral replication preceded the onset of clinical GVHD on both occasions. Their recurrent relation in time confirms the hypothesis that viral reactivation is directly involved in the pathogenesis of GVHD.
HHV6 can infect monocytes and the few CD4 þ T cells that are present after transplantation because of immune suppression due to the lympho-and myeloablative conditioning and or extensive T-cell depletion. 2, 4, 6 Infection of these cells leads to alteration and modification of immune responses, further facilitating viral replication and creating an environment adept for further viral reactivation. 2, 6 Because of the exposure of the recovering immune system to this massive amount of HHV6 Ags, a large number of cells become activated; including the few allo-reactive T cells. 2 This imbalance in immune response promotes the development of GVHD, further enhanced by upregulation of HLA class I and II molecules by the virus. 7 Theoretically, HHV6 induced cytokine release could also have a function in this process. 7, 8 HHV6 also induces tissue damage, which further functions as trigger for the development of GVHD. 2 Once GVHD has developed, it can cause a vicious cycle of impairment of the immune system in which reactivated HHV6 infects and destroys NK-cells, T-lymphocytes, monocytes and so on, leading to further imbalance of the immune system and more tissue damage. 9, 10 This cascade can lead to fatal immune suppression and disseminated HHV6 infection as has been reported, but on the other hand also fulminant lethal GVHD caused by the enhanced T-cell responses and cytokine release.
In conclusion, we hypothesize that the observed severe GVHD in this patient was induced by reactivated HHV6-driven allo-immune stimulation. We suggest standard measurement of HHV6 PCR in patients with GVHD after haplo-SCT. If reactivation is present this should also be treated in order to stop this cascade of deleterious events, thereby improving outcome.
